Drug makers, insurers and pharmacy benefit managers face mounting pressure from Congress and the public to reduce the high list prices of drugs like insulin.
Published: April 3, 2019 at 02:00AM
from NYT Health https://ift.tt/2FSv7Zc
Drug makers, insurers and pharmacy benefit managers face mounting pressure from Congress and the public to reduce the high list prices of drugs like insulin.
Published: April 3, 2019 at 02:00AM
from NYT Health https://ift.tt/2FSv7Zc